Thilo Albert

Bonn, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

On Factor VIII Assay Discrepancies in Post-infusion Samples Obtained from Patients Treated with Efanesoctocog Alfa.

On Factor VIII Assay Discrepancies in Post-infusion Samples Obtained from Patients Treated with Efanesoctocog Alfa.

Journal: Hamostaseologie

Published: January 19, 2026

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: October 22, 2025

Profiling of Anti-FVIII Antibodies in Acquired Haemophilia A: 'Insights into Domain Specificity, Isotype Variability, and Clinical Correlations'.

Profiling of Anti-FVIII Antibodies in Acquired Haemophilia A: 'Insights into Domain Specificity, Isotype Variability, and Clinical Correlations'.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 16, 2025

Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A.

Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: June 03, 2024

Comprehensive domain-specific analysis and immunoglobulin G profiling of anti-factor VIII antibodies using a bead-based multiplex immunoassay.

Comprehensive domain-specific analysis and immunoglobulin G profiling of anti-factor VIII antibodies using a bead-based multiplex immunoassay.

Journal: Journal of thrombosis and haemostasis : JTH

Published: November 14, 2023

Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies.

Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: August 25, 2023

Functional determination of emicizumab in presence of factor VIII activity.

Functional determination of emicizumab in presence of factor VIII activity.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 17, 2023

Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII.

Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII.

Journal: Journal of thrombosis and haemostasis : JTH

Published: September 23, 2022

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.

Journal: The Journal of clinical investigation

Published: March 07, 2022

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

Journal: PloS one

Published: November 15, 2018

Significance of F8 missense mutations with respect to inhibitor formation.

Significance of F8 missense mutations with respect to inhibitor formation.

Journal: Thrombosis and haemostasis

Published: July 27, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026